

# Prevalence and Neighborhood Geomapping of COVID-19 in an Underserved Chicago Pregnant Population

Catalin S. Buhimschi, MD<sup>1</sup> Gloria L. Elam, MD<sup>1</sup> Stephen R. Locher, MD<sup>1</sup> Doreen Norris-Stojak, RN<sup>2</sup> Hayfaa Aldasoqi, CNM<sup>2</sup> Mary D. Stephenson, MD<sup>1</sup> Irina A. Buhimschi, MD<sup>1</sup>

<sup>1</sup>Department of Obstetrics, Gynecology, University of Illinois College of Medicine, Chicago, Illinois

<sup>2</sup> Patient Care Nursing Administration, University of Illinois Hospital and Health Sciences System, Chicago, Illinois

Address for correspondence Catalin S. Buhimschi, MD, MMS, MBA, Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Illinois College of Medicine, 820 South Wood Street (MC 808), Chicago, IL 60612 (e-mail: csb01@uic.edu).


Am J Perinatol Rep 2020;10:e413-e416.

Abstract	<b>Objective</b> The Chicago area is known to harbor some of the deepest racial and ethnic socioeconomic inequalities in the United States. We studied the prevalence and neighborhood distribution of patients who tested positive for COVID-19 after implementation of universal screening at an academic hospital providing obstetrical services to an underserved Chicago population.
	<b>Study Design</b> From April 16 to June 16, 2020, a total of 369 patients were screened for COVID-19 at University of Illinois at Chicago with either the Abbott Point-of-Care (POC, $n = 266$ ) or reverse transcription polymerase chain reaction test (RT-PCR, $n = 101$ ). Patient residential data mapped using ESRI ArcGIS Pro was integrated in ESRI's Living Atlas with the Neighborhood Socioeconomic Status Index (NSEI). <b>Results</b> Precisely, 7.9% (29/369) of screened patients tested positive; 69% (17/29)
Keywords	with the POC test and 31% (12/29) by RT-PCR. The prevalence of an outpatient RT-PCR positive result was 8.9% (9/101). All but one of the 29 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients were either Hispanic or Black, and the majority resided in disadvantaged neighborhoods.
<ul> <li>SARS-CoV-2</li> <li>COVID-19</li> <li>pregnancy</li> <li>racial disparity</li> </ul>	<b>Conclusion</b> The disproportionate hit of COVID-19 pandemic on the Hispanic and Black communities reflects in SARS-CoV-2 positivity rates in the obstetrical population. Our report provides data that may be useful to policy makers when prioritizing resources to communities in need.

Geographic differences in numbers of coronavirus disease 2019 (COVID-19) cases and deaths vary widely across the United States. The University of Illinois at Chicago (UIC) Hospital and Health Sciences System (UIH) serves as a referral site for the seriously ill throughout Chicago, which is the third most populous region in the United States. In response to the COVID-19 pandemic, on March 21, 2020,

received July 17, 2020 accepted after revision September 16, 2020 DOI https://doi.org/ 10.1055/s-0040-1721416. ISSN 2157-6998. Illinois Gov. J.B. Pritzker issued a stay-at-home order.<sup>1</sup> To slow the spread of SARS-CoV-2, on April 16, 2020, UIC/UIH implemented a universal screening protocol for all women presenting for childbirth, management of high-risk antenatal or post-partum conditions, and for elective procedures. The SARS-CoV-2 prevalence in the U.S. pregnant population has ranged from 3.9% (Connecticut) to 13.5% (New York

Copyright © 2020 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA Tel: +1(212) 760-0888.



City). No reports so far have focused on the Chicago area, which harbors one of the greatest racial, ethnic, and health care divides in the country.<sup>2,3</sup>

#### Methods

From April 16 to June 16, 2020, a total of 369 patients were screened with either the Abbott Point-of-Care (POC) platform (n = 266) or RT-PCR (n = 103) using a standardized nasopharyngeal swab protocol. Patients scheduled for elective procedures were screened as outpatients. The diagnosis of mild-to-severe COVID-19 was established based on welldefined Centers for Disease Control and Prevention criteria.<sup>4</sup> All patients had "persons under investigation" status, and full personal protective equipment was used until the results were reported. COVID-19 positive patients were delivered in designated rooms. Prospectively, collected demographic and clinical data were integrated with each subject's self-reported race, ethnicity, and residential address. The ESRI ArcGIS Pro (v2.5) with Living Atlas was used for neighborhood geomapping. The living neighborhoods of the catchment population were mapped using the Neighborhood Socioeconomic Status Index (NSEI) tool.<sup>5</sup> The institutional review board concluded this analysis was not human subject research.

## Results

During the study period, 366 patients were screened for SARS-CoV-2 prior to admission, and 7.9% (29/369) tested positive; 69% (17/29) with the POC and 31% (12/29) with the RT-PCR platforms (**-Table 1**). The prevalence of an outpatient RT-PCR SARS-CoV-2 positive result was 8.9% (9/101). Total testing numbers reached their peak (n = 52/week) 5 weeks postimplementation of the protocol (May 11–17, 2020).

Precisely, 62% (18/29) of SARS-CoV-2 positive patients displayed mild-to-severe COVID-19 symptoms. The remaining 38% (11/29) were asymptomatic. Of the SARS-CoV-2 symptomatic patients, 31% (9/29) were admitted primary due to respiratory COVID-19 signs or symptoms. The other 69% (20/29) presented to the hospital for obstetrical issues, and COVID-19 was diagnosed upon admission by corroborating test positivity with present or past symptomatology (e.g., sore throat, headache, body aches, loss of smell, and/or gastrointes-tinal symptoms). Among SARS-CoV-2 negative patients only 1% (3/340) were admitted primary due to respiratory symptoms (chest pain and pulmonary edema), which in the context of negative viral workup remained of undetermined etiology.

The SARS-CoV-2 positive patients were younger, less frequently married, and more frequently had confounding symptomatology, which led to preeclampsia workup (p < 0.05 for all). All but one of the 29 SARS-CoV-2 positive patients (97%) were either Hispanic or Black, and the vast majority resided in low socioeconomic neighborhoods (**-Fig. 1**). Predominantly Hispanic (e.g., zip 60608, 60609, 60623) or Black (e.g., zip 60827, 60644) neighborhoods accounted for 48% (14/29) and 38% (11/29) of SARS-CoV-2 positive patients, respectively.

 Table 1
 Demographic and clinical characteristics

Positive (n = 29)Negative (n = 340)Age (y) <sup>b, h</sup> 25 (22-30)29 (24-34)Nulliparity <sup>c</sup> 11 (38)110 (32)Marital status <sup>c,h</sup> 2 (7)87 (26)Maried2 (7)87 (26)Race and ethnicity <sup>c,h</sup> 1 (3)87 (26)Race and ethnicity <sup>c,h</sup> 1 (3)91 (2)Black19 (66)191 (56)Hispanic9 (31)65 (19)Other9 (31)65 (19)Other13 (45)179 (53)A11 (38)82 (24)B5 (17)57 (17)A0 (0)41 (3)G0 (0)18 (5)Unknown0 (0)18 (5)Unknown0 (0)21 (6)Second trimester: 14-263 (10)21 (6)Second trimester: preterm: 27-363 (10)23 (7)Third trimester preterm: 27-34015 (52)239 (70)Third trimester preterm: 237-4020 (69)248 (73)Outpatient clinic9 (31)9 (20)SARS-CoV-2 testing type"24 (74)10Unbow point-of- care Abbott17 (69)248 (74)DNOW point-of- care Abbott11 (38)MMild17 (59)248 (74)Severe11 (38)4Mild17 (59)3Severe11 (38)9Delivery mode"31 (44)90 (26)Preclampsia workup <sup>c,h</sup> 13 (44)90 (26)Severe11 (38)9 (26)Seve	Variables <sup>a</sup>	SARS-CoV-2 test result				
Nulliparity11 (38)110 (32)Married2 (7)87 (26)Race and ethnicity87 (26)Race and ethnicity1 (3)39 (12)White non-Hispanic1 (3)39 (12)Black19 (66)191 (56)Hispanic9 (31)65 (19)Other0 (0)45 (13)Blood type <sup>6</sup> 179 (53)A11 (38)82 (24)B5 (17)57 (17)AB0 (0)4 (1)O13 (45)179 (53)AB0 (0)4 (1)GA (wk) <sup>6</sup> 23 (7)First trimester: yreterm: 27-363 (10)23 (7)Third trimester preterm: 27-363 (10)21 (6)Third trimester preterm: 27-363 (10)21 (6)OBER20 (69)248 (73)OUtpatient clinic care Abbott9 (31)92 (27)SARS-CoV-2 testing type*I3ODER20 (69)248 (74)COVID-19 symptoms sever.I3Mild17 (59)8 (26)Severe11 (38)MMild17 (59)88 (26)Preeclampsia workup <sup>C,h</sup> 13 (44)210 (62)Preeclampsia workup <sup>C,h</sup> 13 (44)210 (62)						
Marital status <sup>c.h</sup> 2 (7)         8 7 (26)           Race and ethnicity <sup>c.h</sup> 39 (12)           White non-Hispanic         1 (3)         39 (12)           Black         19 (66)         191 (56)           Hispanic         9 (31)         65 (19)           Other         0 (0)         45 (13)           Blood type <sup>c</sup> 11 (38)         82 (24)           B         5 (17)         57 (17)           A         11 (38)         82 (24)           B         5 (17)         57 (17)           AB         0 (0)         4 (1)           GA (wk) <sup>c</sup> 5 (17)         57 (17)           AB         0 (0)         4 (1)           GA (wk) <sup>c</sup> 23 (7)         54           First trimester:         3 (10)         21 (6)           14-26         3 (10)         21 (6)           Third trimester         8 (28)         52 (16)           preterm:         27-36         239 (70)           Third trimester         9 (31)         92 (27)           SARS-CoV-2 testing type <sup>C</sup> 248 (73)           Outpatient clinic         9 (31)         92 (27)           SARS-CoV-2 testing type <sup>C</sup> 248 (74) </td <td>Age (y)<sup>b, h</sup></td> <td>25 (22–30)</td> <td>29 (24–34)</td>	Age (y) <sup>b, h</sup>	25 (22–30)	29 (24–34)			
Married2 (7)87 (26)Race and ethnicity <sup>c,h</sup> 139 (12)White non-Hispanic1 (3)39 (12)Black19 (66)191 (56)Hispanic9 (31)65 (19)Other0 (0)45 (13)Blood type <sup>c</sup> 11 (38)82 (24)B5 (17)57 (17)AB0 (0)18 (5)Unknown0 (0)4 (1)GA (wk) <sup>c</sup> 11 (38)23 (7)First trimester: $< < 14$ 3 (10)21 (6)Second trimester: $27 - 36$ 3 (10)21 (6)Third trimester 	Nulliparity <sup>c</sup>	11 (38)	110 (32)			
Race and ethnicity <sup>c,h</sup> I (3)         39 (12)           White non-Hispanic         1 (3)         39 (12)           Black         19 (66)         191 (56)           Hispanic         9 (31)         65 (19)           Other         0 (0)         45 (13)           Blood type <sup>6</sup> 179 (53)         A           O         13 (45)         179 (53)           A         11 (38)         82 (24)           B         5 (17)         57 (17)           AB         0 (0)         18 (5)           Unknown         0 (0)         4 (1)           GA (wk) <sup>c</sup>	Marital status <sup>c,h</sup>					
White non-Hispanic         1 (3)         39 (12)           Black         19 (66)         191 (56)           Hispanic         9 (31)         65 (19)           Other         0 (0)         45 (13)           Blood type <sup>6</sup> 179 (53)         179 (53)           A         11 (38)         82 (24)           B         5 (17)         57 (17)           AB         0 (0)         18 (5)           Unknown         0 (0)         4 (1)           GA (wk) <sup>6</sup>		2 (7)	87 (26)			
non-Hispanic         Interface         Parameter           Black         19 (66)         191 (56)           Hispanic         9 (31)         65 (19)           Other         0 (0)         45 (13)           Blood type <sup>c</sup> 13 (45)         179 (53)           A         11 (38)         82 (24)           B         5 (17)         57 (17)           AB         0 (0)         18 (5)           Unknown         0 (0)         4 (1)           GA (wk) <sup>c</sup>	Race and ethnicity <sup>c,h</sup>					
Hispanic       9 (31)       65 (19)         Other       0 (0)       45 (13)         Blood type <sup>c</sup> 13 (45)       179 (53)         A       11 (38)       82 (24)         B       5 (17)       57 (17)         AB       0 (0)       18 (5)         Unknown       0 (0)       4 (1)         GA (wk) <sup>c</sup> 11 (38)       23 (7)         First trimester:       3 (10)       21 (6)         14-26       3 (10)       21 (6)         Second trimester:       3 (10)       21 (6)         14-26       3 (10)       21 (6)         Third trimester       8 (28)       52 (16)         preterm:       27-36       239 (70)         Third trimester       15 (52)       239 (70)         term: ≥37-40       0 (0)       5 (1)         Postpartum       0 (0)       5 (1)         Hospital testing site <sup>c</sup> 20 (69)       248 (73)         Outpatient clinic       9 (31)       92 (27)         SARS-CoV-2 testing type <sup>c</sup> 21       1         ID NOW point-of-care Abbott       17 (69)       248 (74)         Central laboratory RT-PCR       17 (69)       248 (74)         M		1 (3)	39 (12)			
Other         0 (0)         45 (13)           Blood type <sup>c</sup> 13 (45)         179 (53)           A         11 (38)         82 (24)           B         5 (17)         57 (17)           AB         0 (0)         18 (5)           Unknown         0 (0)         4 (1)           GA (wk) <sup>c</sup> 23 (7)         (14)           First trimester:         3 (10)         21 (6)           14-26         3 (10)         21 (6)           Third trimester         3 (10)         52 (16)           preterm:         27-36         239 (70)           Third trimester         15 (52)         239 (70)           Third trimester         9 (31)         92 (27)           Postpartum         0 (0)         5 (1)           Hospital testing site <sup>c</sup> 20 (69)         248 (73)           Outpatient clinic         9 (31)         92 (27)           SARS-CoV-2 testing type <sup>c</sup> 17 (69)         248 (74)           Central laboratory         17 (69)         248 (74)           RT-PCR         11 (38)         89 (26)           Severe         11 (38)         90 (26)           Mild         17 (59)         248 (26)	Black	19 (66)	191 (56)			
Blood type <sup>c</sup> 13 (45)179 (53)A11 (38)82 (24)B5 (17)57 (17)AB0 (0)18 (5)Unknown0 (0)4 (1)GA (wk) <sup>c</sup> 23 (7)First trimester: $<14$ 3 (10)21 (6)14-263 (10)21 (6)Third trimester preterm: $27-36$ 8 (28)52 (16)Third trimester term: $\geq 37-40$ 15 (52)239 (70)Postpartum0 (0)5 (1)Hospital testing site <sup>c</sup> 20 (69)248 (73)Outpatient clinic9 (31)92 (27)SARS-CoV-2 testing type <sup>c</sup> 17 (69)248 (74)CoVID-19 symptoms severt <sup>c,c,d</sup> 89 (26)COVID-19 symptoms severt <sup>c,c,d</sup> NAMild17 (59)88 (26)Preclampsia workup <sup>c,h</sup> 13 (44)210 (62)Preclampsia workup <sup>c,h</sup> 13 (44)210 (62)	Hispanic	9 (31)	65 (19)			
O13 (45)179 (53)A11 (38)82 (24)B5 (17)57 (17)AB0 (0)18 (5)Unknown0 (0)4 (1)GA (wk) <sup>c</sup> 23 (7)First trimester: $<14$ 3 (10)23 (7)Second trimester: 14-263 (10)21 (6)Third trimester preterm: 27-363 (10)21 (6)Third trimester preterm: $27-36$ 8 (28)52 (16)Third trimester term: $\geq 37-40$ 15 (52)239 (70)Postpartum0 (0)5 (1)Hospital testing site <sup>c</sup> 20 (69)248 (73)Outpatient clinic9 (31)92 (27)SARS-CoV-2 testing type <sup>c</sup> 17 (69)248 (74)COVID-19 symptoms severtyc.d12 (31)89 (26)COVID-19 symptoms severtyc.d11 (38)NAMild17 (59)13 (45)88 (26)Preeclampsia workup <sup>c.h</sup> 13 (44)210 (62)		0 (0)	45 (13)			
A       11 (38)       82 (24)         B       5 (17)       57 (17)         AB       0 (0)       18 (5)         Unknown       0 (0)       4 (1)         GA (wk) <sup>c</sup> 23 (7)         First trimester:       3 (10)       23 (7)         <14	Blood type <sup>c</sup>					
B         5 (17)         57 (17)           AB         0 (0)         18 (5)           Unknown         0 (0)         4 (1)           GA (wk) <sup>c</sup> 23 (7)           First trimester:         3 (10)         23 (7)           <14	0	13 (45)	179 (53)			
AB         0 (0)         18 (5)           Unknown         0 (0)         4 (1)           GA (wk) <sup>c</sup>	A	11 (38)	82 (24)			
Unknown         0 (0)         4 (1)           GA (wk) <sup>c</sup> $-$ First trimester:         3 (10)         23 (7)           <14 $ -$ Second trimester:         3 (10) $21$ (6)           14-26 $3$ (10) $21$ (6)           Third trimester $3$ (10) $21$ (6)           Third trimester $8$ (28) $52$ (16)           preterm: $27-36$ $239$ (70)           Third trimester $15$ (52) $239$ (70)           term: $237-40$ $0$ (0) $5$ (1)           Postpartum $0$ (0) $5$ (1)           Hospital testing site <sup>c</sup> $0$ $92$ (27)           OBER $20$ (69) $248$ (73)           Outpatient clinic $9$ (31) $92$ (27)           SARS-CoV-2 testing type <sup>c</sup> $248$ (74) $36$ CoVID-19 symptoms severt $31$ (69) $248$ (74)           CoVID-19 symptoms severt <sup>c,d</sup> $39$ (26) $36$ Mild $17$ (59) $36$ $36$ Severe $11$ (38) $90$ (26)	В	5 (17)				
GA (wk) <sup>c</sup> 3 (10)       23 (7)         First trimester:       3 (10)       21 (6)         14-26       3 (10)       21 (6)         Third trimester       8 (28)       52 (16)         preterm:       27-36       15 (52)       239 (70)         Third trimester       15 (52)       239 (70)         term: $\geq 37-40$ 0 (0)       5 (1)         Postpartum       0 (0)       5 (1)         Hospital testing site <sup>C</sup> 20 (69)       248 (73)         Outpatient clinic       9 (31)       92 (27)         SARS-CoV-2 testing type <sup>C</sup> 17 (69)       248 (74)         Central laboratory       12 (31)       89 (26)         RT-PCR       11 (38)       NA         Mild       17 (59)       90 (26)         Severe       1 (3)       13 (45)       88 (26)         Preeclampsia       13 (45)       88 (26)       210 (62)         Delivery mode <sup>C</sup> 13 (44)       210 (62)       210 (62)	AB	0 (0)	18 (5)			
First trimester:       3 (10)       23 (7) $< 14$ 3 (10)       21 (6)         Second trimester:       3 (10)       21 (6) $14-26$ 8 (28)       52 (16)         Third trimester       8 (28)       52 (16)         preterm:       27-36       15 (52)       239 (70)         Third trimester       15 (52)       239 (70)         term: $\geq 37-40$ 0 (0)       5 (1)         Postpartum       0 (0)       5 (1)         Hospital testing site <sup>c</sup> 20 (69)       248 (73)         Outpatient clinic       9 (31)       92 (27)         SARS-CoV-2 testing type <sup>c</sup> 17 (69)       248 (74)         Central laboratory       12 (31)       89 (26)         RT-PCR       12 (31)       89 (26)         COVID-19 symptoms severty <sup>c,d</sup> 89 (26)       11 (38)         Mild       17 (59)       90 (26)         Severe       1 (3)       90 (26)         Preeclampsia       13 (45)       88 (26)         workup <sup>c,h</sup> 13 (44)       210 (62)	Unknown	0 (0)	4 (1)			
$<14$ 14       21 (6)         Second trimester:       3 (10)       21 (6)         14-26       8 (28)       52 (16)         Third trimester       8 (28)       52 (16)         preterm:       27-36       239 (70)         Third trimester       15 (52)       239 (70)         term: $\geq 37-40$ 0 (0)       5 (1)         Postpartum       0 (0)       5 (1)         Hospital testing site <sup>c</sup> 0 (69)       248 (73)         Outpatient clinic       9 (31)       92 (27)         SARS-CoV-2 testing type <sup>c</sup> 20 (69)       248 (74)         Central laboratory       17 (69)       248 (74)         COVID-19 symptoms severt <sup>c,d</sup> 89 (26)       89 (26)         Mild       17 (59)       89 (26)         Severe       11 (38)       NA         Mild       17 (59)       90 (26)         Preeclampsia workup <sup>c,h</sup> 13 (45)       88 (26)         Delivery mode <sup>c</sup> 13 (44)       210 (62)	GA (wk) <sup>c</sup>					
14-26       1       1         Third trimester preterm: 27-36       8 (28)       52 (16)         Third trimester term: $\geq 37-40$ 15 (52)       239 (70)         Postpartum       0 (0)       5 (1)         Hospital testing site <sup>c</sup> 0 (0)       5 (1)         OBER       20 (69)       248 (73)         Outpatient clinic       9 (31)       92 (27)         SARS-CoV-2 testing type <sup>c</sup> 9 (31)       92 (27)         SARS-CoV-2 testing type <sup>c</sup> 17 (69)       248 (74)         Central laboratory RT-PCR       17 (69)       248 (74)         COVID-19 symptoms severts       89 (26)       11 (38)         Mild       17 (59)       11 (38)       NA         Mild       17 (59)       13 (45)       88 (26)         Preeclampsia workup <sup>c,h</sup> 13 (45)       88 (26)         Delivery mode <sup>c</sup> 13 (44)       210 (62)		3 (10)	23 (7)			
preterm: 27-36         I         I           Third trimester term: $\geq$ 37-40         15 (52)         239 (70)           Postpartum         0 (0)         5 (1)           Hospital testing site <sup>c</sup> 0 (0)         5 (1)           OBER         20 (69)         248 (73)           Outpatient clinic         9 (31)         92 (27)           SARS-CoV-2 testing type <sup>c</sup> 9 (31)         92 (27)           SARS-CoV-2 testing type <sup>c</sup> 248 (74)         248 (74)           Central laboratory RT-PCR         12 (31)         89 (26)           OVID-19 symptoms severty <sup>c,d</sup> 89 (26)         90 (26)           Mild         17 (59)         11 (38)         NA           Mild         17 (59)         88 (26)         90 (26)           Preeclampsia workup <sup>c,h</sup> 13 (45)         88 (26)         90 (26)           Delivery mode <sup>c</sup> 13 (44)         210 (62)         90 (26)		3 (10)	21 (6)			
term: ≥37-40         I         I           Postpartum         0 (0)         5 (1)           Hospital testing site <sup>c</sup> 20 (69)         248 (73)           OBER         20 (69)         92 (27)           SARS-CoV-2 testing type <sup>c</sup> 9 (31)         92 (27)           SARS-CoV-2 testing type <sup>c</sup> 17 (69)         248 (74)           Central laboratory RT-PCR         17 (69)         248 (74)           COVID-19 symptoms severty <sup>c,d</sup> 89 (26)         12 (31)           Mild         17 (59)         14 (38)           Mild         17 (59)         14 (38)           Hypertension <sup>c,e</sup> 11 (38)         90 (26)           Preeclampsia workup <sup>c,h</sup> 13 (45)         88 (26)           Delivery mode <sup>c</sup> 13 (44)         210 (62)	preterm:	8 (28)	52 (16)			
Hospital testing site <sup>c</sup> 20 (69)         248 (73)           OBER         20 (69)         92 (27)           SARS-CoV-2 testing type <sup>c</sup> 9 (31)         92 (27)           SARS-CoV-2 testing type <sup>c</sup> 17 (69)         248 (74)           Central laboratory RT-PCR         12 (31)         89 (26)           COVID-19 symptoms severty <sup>c,d</sup> 89 (26)         11 (38)           Mild         17 (59)         14 (38)         NA           Mild         17 (59)         11 (38)         90 (26)           Preeclampsia workup <sup>c,h</sup> 13 (45)         88 (26)         26)           Delivery mode <sup>c</sup> 13 (44)         210 (62)         13 (44)		15 (52)	239 (70)			
OBER         20 (69)         248 (73)           Outpatient clinic         9 (31)         92 (27)           SARS-CoV-2 testing type <sup>c</sup> 248 (74)           ID NOW point-of- care Abbott         17 (69)         248 (74)           Central laboratory RT-PCR         12 (31)         89 (26)           COVID-19 symptoms severty <sup>c,d</sup> Asymptomatic         11 (38)         NA           Mild         17 (59)            Severe         1 (3)            Hypertension <sup>c,e</sup> 11 (38)         90 (26)           Preeclampsia workup <sup>c,h</sup> 13 (45)         88 (26)           Delivery mode <sup>c</sup> Vaginal delivery         13 (44)         210 (62)	Postpartum	0 (0)	5 (1)			
Outpatient clinic         9 (31)         92 (27)           SARS-CoV-2 testing type <sup>c</sup> ID NOW point-of- care Abbott         17 (69)         248 (74)           Central laboratory RT-PCR         12 (31)         89 (26)           COVID-19 symptoms severty <sup>c,d</sup> Asymptomatic         11 (38)         NA           Mild         17 (59)            Severe         1 (3)         90 (26)           Preeclampsia workup <sup>c,h</sup> 13 (45)         88 (26)           Delivery mode <sup>c</sup> Vaginal delivery         13 (44)         210 (62)						
SARS-CoV-2 testing typecID NOW point-of-care Abbott17 (69)248 (74)Central laboratory RT-PCR12 (31)89 (26)COVID-19 symptoms severtyc.d2000000000000000000000000000000000000	OBER	20 (69)	248 (73)			
ID NOW point-of-care Abbott17 (69)248 (74)Central laboratory RT-PCR12 (31)89 (26)COVID-19 symptoms severityc,d2000000000000000000000000000000000000	Outpatient clinic	9 (31)	92 (27)			
care AbbottdefendenceCentral laboratory RT-PCR12 (31)89 (26)COVID-19 symptoms severtyc,dAsymptomatic11 (38)NAMild17 (59)Severe1 (3)Hypertension <sup>c,e</sup> 11 (38)90 (26)Preeclampsia workup <sup>c,h</sup> 13 (45)88 (26)Delivery mode <sup>c</sup> Vaginal delivery13 (44)210 (62)						
RT-PCRRt and a constructionCOVID-19 symptoms severityNAAsymptomatic11 (38)Mild17 (59)Severe1 (3)Hypertension11 (38)Preeclampsia workup13 (45)Belivery mode210 (62)		17 (69)	248 (74)			
Asymptomatic         11 (38)         NA           Mild         17 (59)	,	12 (31)	89 (26)			
Mild         17 (59)           Severe         1 (3)           Hypertension <sup>c,e</sup> 11 (38)           Preeclampsia workup <sup>c,h</sup> 13 (45)           Delivery mode <sup>c</sup> 13 (44)           Vaginal delivery         13 (44)	COVID-19 symptoms severity <sup>c,d</sup>					
Severe         1 (3)           Hypertension <sup>c,e</sup> 11 (38)         90 (26)           Preeclampsia workup <sup>c,h</sup> 13 (45)         88 (26)           Delivery mode <sup>c</sup> 13 (44)         210 (62)	Asymptomatic	11 (38)	NA			
Hypertensionc,e11 (38)90 (26)Preeclampsia workupc,h13 (45)88 (26)Delivery modecVaginal delivery13 (44)210 (62)	Mild	17 (59)				
Preeclampsia workup <sup>c,h</sup> 13 (45)88 (26)Delivery modecVaginal delivery13 (44)210 (62)	Severe	1 (3)				
workup <sup>c,h</sup> Image: Constraint of the second seco	Hypertension <sup>c,e</sup>	11 (38)	90 (26)			
Vaginal delivery         13 (44)         210 (62)	Preeclampsia workup <sup>c,h</sup>	13 (45)	88 (26)			
	Delivery mode <sup>c</sup>					
Cesarean delivery 7 (24) 79 (23)	Vaginal delivery	13 (44)	210 (62)			
	Cesarean delivery	7 (24)	79 (23)			

Variables <sup>a</sup>	SARS-CoV-2 test result		
	Positive (n = 29)	Negative (n = 340)	
Unknown <sup>f</sup>	9 (31)	51 (15)	
Neonatal SARS-CoV- 2 positive test <sup>c,g</sup>	0 (0)	NA	

Table 1 (Continued)

Abbreviations: GA, gestational age; NA, not applicable; OBER, obstetrical emergency room unit; RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup>Data analyzed using SigmaPlot (v12.5 Systat, San Jose, CA).

<sup>b</sup>Data presented as median (interquartile range) and analyzed by Wilcoxon's rank-sum test.

<sup>c</sup>Data presented as no (%) and analyzed by Chi-square test.

<sup>d</sup>Presence of illness and severity of COVID-19 was assessed clinically using the American College of Obstetricians and Gynecologists recommended algorithm with slight institutional modifications.

<sup>e</sup>Defined as blood pressure  $\geq$ 140 mm Hg (systolic) and/or  $\geq$ 90 mm Hg (diastolic).

<sup>f</sup>Accounts for ongoing pregnancies or transfer to care to other health care facilities.

<sup>9</sup>All newborns were for COVID-19 positive mothers were tested in the neonatal intensive care unit by RT-PCR.

 $^{h}p < 0.05.$ 

## Discussion


Compared with other regions of the country, except New York City, this analysis identified a higher prevalence of

positive SARS-CoV-2 test results in our underserved Chicago population than previously reported for another obstetrical population in Connecticut.<sup>3</sup> The 7.9% test positivity identified in our institution is also higher than the 5.5% positivity reported by the city of Chicago for the same time period.<sup>6</sup>

Chicago has a long history of Black and Hispanic racial neighborhood segregation.<sup>7</sup> The NSEI index tool showed that the vast majority of Chicago women in the UIC/UIH catchment area who tested SARS-CoV-2 positive were Hispanic or Black and resided in low socioeconomic status neighborhoods. Chicago minority populations are known to be disproportionally affected by the SARS-CoV2 pandemic, and our data suggest that this is reflected in COVID-19 positivity rates among obstetrical patients.

A positive COVID-19 test during pregnancy has important consequences. For patients who are symptomatic, there are obvious concerns related to maternal and fetal well-being due to the heightened state of inflammation and potential for diminished oxygen supply to the placenta and fetus. For patients who remain asymptomatic, COVID-19 positivity changes their pregnancy and delivery experience given the need of shielding the newborn from maternal exposure and of protecting the medical staff during patient-provider encounters.<sup>8</sup>

Limitations of this study include the single institution and relatively short duration of analysis. Allocation of appropriate educational and financial resources to vulnerable pregnant populations residing in disadvantaged Chicago neighborhoods is needed.



**Fig. 1** Overlay of the screened population with the NSEI. The NSEI varies from 0 to 100. A score of 50 represents the national average. NSEI incorporates the median household income, percent households with income below the Federal Poverty Line, educational attainment of adults (age 25 + ), rate of unemployment, and percent of households with children under the age of 18 that are "female headed" (no male present). Data for NSEI come from the U.S. Census Bureau 2011 to 2015 American Community Survey as implemented in ArcGIS's Living Atlas. Original map scale 1:400,000. Areas intensely purple have high NSEI and white areas have low NSEI. NSEI, Neighborhood Socioeconomic Index; UIC/UIH, University of Illinois at Chicago/ Hospital and Health Sciences System.

Authors' Contributions

C.S.B. had full access to all of the data in the study and takes responsibility for the integrity and accuracy of data analysis. C.S.B, L.G.E., S.R.L., D.N.S., H.A., M.D.S, and I.A.B. supported in conceiving the concept and design, and performed analysis or interpretation of data. H.A., I.A.B., and C.S.B. involved in data collection. I.A.B. and C.S.B. dedicated in drafting of the manuscript and statistical analysis. C.S.B, L.G.E., D.N.S., S.R.L., and M.D.S coordinated in supervision. All authors carried out the critical revision of the manuscript for important intellectual content.

Conflict of Interest None declared.

#### References

1 https://www.illinoispolicy.org/pritzker-orders-illinoisans-toshelter-in-place-until-april-7/

- 2 Sutton D, Fuchs K, D'Alton M, Goffman D. Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med 2020; 382(22):2163–2164
- <sup>3</sup> Campbell KH, Tornatore JM, Lawrence KE, et al. Prevalence of SARS-CoV-2 among patients admitted for childbirth in Southern Connecticut. JAMA 2020;323(24):2520–2522
- 4 Symptoms of Coronavirus Accessed 2020https://www.cdc.gov/ coronavirus/2019-ncov/symptoms-testing/symptoms.html
- 5 Miles JN, Weden MM, Lavery D, Escarce JJ, Cagney KA, Shih RA. Constructing a time-invariant measure of the socio-economic status of U.S. census tracts. J Urban Health 2016;93(01):213–232
- 6 COVID Dashboard Queried on August 3 for period April 16, 2020 to June 16, 2020 at https://www.chicago.gov/city/en/sites/covid-19/ home/covid-dashboard.html
- 7 Matoba N, Reina M, Prachand N, Davis MM, Collins JW. Neighborhood gun violence and birth outcomes in Chicago. Matern Child Health J 2019;23(09):1251–1259
- 8 Stanojević M. Are Covid-19-positive mothers dangerous for their term and well newborn babies? Is there an answer?. J Perinat Med 2020;48(05):441–445